[OneMedForum] Immunocellular Therapeutics

The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.

Read more »

[OneMedForum] OrSense: Non-Invasive Blood Monitoring Solutions

Israel-based OrSense is attempting to increase patient compliance with a non-invasive continuous glucose monitor based on optical technology.

Read more »

[OneMedForum] Jaleva Pharmaceuticals

One company presenting at the conference is San Diego-based Jaleva Pharmaceuticals, which has developed a resin-based delivery vehicle for topical medications.

Read more »

Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts

Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.

Read more »

EyeGate Raises $22.6M In Venture Funding

The money will be used to further the company’s development of EGP-437 to treat dry eye syndrome.

Read more »

Enzon and Sopherion Make Breast Cancer Progress

Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.

Read more »

As Seasonal Flu Ramps Up, NexBio Begins Phase II Trial for DAS181

DAS181 is formulated to prevent the influenza virus from entering cells in the respiratory tract.

Read more »

NeoPharm to Investigate Treatment for Deadly Lung Disease

The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.

Read more »